Haematologica
Ferrata Storti Foundation
image
Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy
Volume: 105, Issue: 5
DOI 10.3324/haematol.2019.227561
  •       

Table of Contents

Highlights

Notes

Abstract

Although studies of mixed chimerism following hematopoietic stem cell transplantation in patients with sickle cell disease (SCD) may provide insights into the engraftment needed to correct the disease and into immunological reconstitution, an extensive multilineage analysis is lacking. We analyzed chimerism simultaneously in peripheral erythroid and granulomonocytic precursors/progenitors, highly purified B and T lymphocytes, monocytes, granulocytes and red blood cells (RBC). Thirty-four patients with mixed chimerism and ≥12 months of follow-up were included. A selective advantage of donor RBC and their progenitors/precursors led to full chimerism in mature RBC (despite partial engraftment of other lineages), and resulted in the clinical control of the disease. Six patients with donor chimerism <50% had hemolysis (reticulocytosis) and higher HbS than their donor. Four of them had donor chimerism <30%, including a patient with AA donor (hemoglobin >10 g/dL) and three with AS donors (hemoglobin <10 g/dL). However, only one vaso-occlusive crisis occurred with 68.7% HbS. Except in the patients with the lowest chimerism, the donor engraftment was lower for T cells than for the other lineages. In a context of mixed chimerism after hematopoietic stem cell transplantation for SCD, myeloid (rather than T cell) engraftment was the key efficacy criterion. Results show that myeloid chimerism as low as 30% was sufficient to prevent a vaso-occlusive crisis in transplants from an AA donor but not constantly from an AS donor. However, the correction of hemolysis requires higher donor chimerism levels (i.e. ≥50%) in both AA and AS recipients. In the future, this group of patients may need a different therapeutic approach.

https://www.researchpad.co/tools/openurl?pubtype=article&doi=10.3324/haematol.2019.227561&title=Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy&author=Alessandra Magnani,Corinne Pondarré,Naïm Bouazza,Jeremy Magalon,Annarita Miccio,Emmanuelle Six,Cecile Roudaut,Cécile Arnaud,Annie Kamdem,Fabien Touzot,Aurélie Gabrion,Elisa Magrin,Chloé Couzin,Mathieu Fusaro,Isabelle André,Jean-Paul Vernant,Eliane Gluckman,Françoise Bernaudin,Dominique Bories,Marina Cavazzana,&keyword=&subject=Articles,Red Cell BIology & its Disorders,